Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia

Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989

  • Joel Morganroth
  • E. Neil Moore

Part of the Developments in Cardiovascular Medicine book series (DICM, volume 112)

Table of contents

  1. Front Matter
    Pages i-x
  2. Approaches and Methods to Studying Antihypertensive Drugs

  3. What Should be Required for FDA Approvability of a New Antihypertensive Drug?

  4. Surrogate Endpoints to Define Risk vs. Benefits

  5. Back Matter
    Pages 224-230

About this book

Introduction

The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect.

Keywords

blood pressure cardiovascular cardiovascular disease clinical research clinical trial drug drug research drugs heart heart disease heart failure hypertension lipide research vascular disease

Editors and affiliations

  • Joel Morganroth
    • 1
  • E. Neil Moore
    • 2
  1. 1.Likoff Cardiovascular Institute of Hahnemann Medical College and HospitalUSA
  2. 2.School of Veterinary MedicineUniversity of PennsylvaniaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4613-1505-6
  • Copyright Information Springer-Verlag US 1990
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4612-8809-1
  • Online ISBN 978-1-4613-1505-6
  • Series Print ISSN 0166-9842
  • About this book
Industry Sectors
Health & Hospitals
Biotechnology
Pharma